Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.

NCT06858319 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

220

Enrollment

INDUSTRY

Sponsor class

Conditions

Kidney Diseases
Kidney Diseases, Chronic
Urological Diseases
Glomerulonephritis
Glomerular Disease
Glomerulonephritis, IGA
Glomerulopathy
Immunoglobulin Disease

Interventions

DRUG: zigakibart

Sponsor

Novartis Pharmaceuticals